Non-Small Cell Lung Cancer (NSCLC)

This video segment explores the critical role of biomarker testing in identifying patients with ALK-positive NSCLC, discussing the clinical characteristics that guide the use of ALK inhibitors and addressing challenges in implementing comprehensive molecular testing in community settings.

A panel of experts review a case of a 55-year-old mom and high school teacher who received lorlatinib for ALK+ NSCLC with brain metastases.

Taletrectinib demonstrated favorable efficacy and tolerability data in the TRUST-I and TRUST-II trials for the treatment of patients with advanced non–small cell lung cancer.

Data from the phase 3 eXalt3 trial support the approval of ensartinib in adult patients with metastatic ALK-positive non–small cell lung cancer.

The phase 3 KeyVibe-003, KeyVibe-007, and KEYFORM-008 trials investigating vibostolimab and favezelimab have been discontinued.

The 2 main pafolacianine components, a folate analog and a dye, are commonly used in other medical applications.

An intravenous infusion administered prior to surgery enables treatment to occur in a normal time frame without the need for additional procedural time.

These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.

Zenocutuzumab is now approved for patients with NRG1 fusion-positive NSCLC or pancreatic adenocarcinoma.

For patients with EGFR-mutated non–small cell lung cancer, sacituzumab tirumotecan was given the breakthrough drug designation by the FDA.

Despite gaps in biomarker testing accessibility, the lung cancer survival rate has improved by 26% over the last 5 years.

Tiragolumab with atezolizumab, when compared with placebo with atezolizumab, failed to reach its overall survival end point in patients with NSCLC.

Results from the TRIDENT-1 and CARE trials, which showcased durable activity and robust responses with repotrectinib, supported the recommendation.

For patients with NSCLC, subcutaneous pembrolizumab appeared noninferior vs intravenous pembrolizumab for study end points when combined with chemotherapy.

FoundationOne Liquid CDx has been approved as a diagnostic tool for tepotinib in patients with non–small cell lung cancer METex14 skipping alterations.

Personalized therapy for non–small cell lung cancer has evolved significantly with the advent of comprehensive molecular testing.

Data from TROPION-Lung05, TROPION-Lung01, and TROPION-PanTumor01 support the new BLA for dato-DXd in advanced or metastatic EGFR-mutated NSCLC.

Treatment with THIO/cemiplimab was generally well-tolerated among patients with advanced NSCLC in the phase 2 THIO-101 study.

Glycan editing of cell surface glycans with E-602 may represent a novel therapeutic approach among patients with cancer.

Detection of S15 and PD-L1 proteins in more than half of NSCLC samples support the potential to target both pathways during treatment.

Updated OS findings from the PERLA trial showed continued success with dostarlimab plus chemotherapy in patients with advanced non–small cell lung cancer.

Treatment with domvanalimab/zimberelimab also improved progression-free survival vs platinum-based chemotherapy in the phase 3 ARC-10 study.

Patients with non–small cell lung cancer had a positive long-term benefit with perioperative chemoimmunotherapy, according to the 5-year NADIM trial update.

Data from the AcceleRET-Lung trial show an imbalanced risk of severe and fatal infection with pralsetinib for patients with RET fusion-positive NSCLC.

Phase 1 expansion data may support potential combination development for IDE397 in NSCLC and urothelial cancer harboring MTAP deletions.